Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the National Cancer Institute

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djp402PMID 19893008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

  2009cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.

  2005cited by this paper
• Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples

  2004cited by this paper
• Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.

  2004cited by this paper
• Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.

  1997cited by this paper

• The precise chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus the classic chemotherapy in the treatment of breast cancer: a comparative effectiveness research

  2019cites this paper
• Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer

  2013cites this paper
• Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

  2013cites this paper
• Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas

  2013cites this paper
• Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis

  2013influential citation
• An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort

  2013cites this paper
• Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort

  2013cites this paper
• Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer

  2012cites this paper
• Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab

  2012cites this paper
• Biomarkers characterization of circulating tumour cells in breast cancer patients

  2012cites this paper
• TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

  2012cites this paper
• Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  2011cites this paper
• Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

  2011cites this paper